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Abstract
Background: Lowering of blood pressure by antihypertensive drugs reduces the risks of cardiovascular events,
stroke, and total mortality. However, poor adherence to antihypertensive medications reduces their effectiveness
and increases the risk of adverse events. In terms of relative risk reduction, an improvement in medication
adherence could be as effective as the development of a new drug.
Methods/Design: The proposed randomized controlled trial will include patients with a low adherence to
medication and uncontrolled blood pressure. The intervention group will receive a multifactorial intervention
during the first, third, and ninth months, to improve adherence. This intervention will include motivational
interviews, pill reminders, family support, blood pressure self-recording, and simplification of the dosing regimen.
Measurement: The primary outcome is systolic blood pressure. The secondary outcomes are diastolic blood
pressure, proportion of patients with adequately controlled blood pressure, and total cost.
Discussion: The trial will evaluate the impact of a multifactorial adherence intervention in routine clinical practice.
Ethical approval was given by the Ethical Committee on Human Research of Balearic islands, Spain (approval
number IB 969/08 PI).
Trial registration: Current controlled trials ISRCTN21229328
Background
T h ep r e v a l e n c eo fh y p e r t e n s ion is about 35% for adults
in general, about 40% for middle-aged individuals, and
up to 68% for elderly individuals [1-3]. Most popula-
tion-based studies confirm that hypertension increases
the risk for cardiovascular events. For example, a recent
meta-analysis indicated a continuous, strong, and graded
relationship between blood pressure (BP) and the occur-
rence of atherosclerotic events [4]. Numerous antihyper-
tensive agents can effectively lower BP and significantly
reduce stroke, coronary heart disease, cardiovascular
death and total mortality by 30-40%, 20-21%, 26-28%,
and 13-16% respectively [5]. However, in clinical prac-
tice, hypertension can be difficult to control. It is esti-
mated that only 40% of primary care hypertensive
patients have BP below 140/90 mmHg, or below 130/80
mmHg for patients with diabetes or renal failure [6].
Clinical inertia and low adherence to medication are
considered the major modifiable causes of poor BP con-
trol [7,8]. Adherence can be defined as the extent to
which patients follow the instructions they are given for
prescribed treatments. The prevalence of low adherence
to antihypertensive drug therapy (AHT) has been
estimated as 30-50% [9,10], and patients with poor
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A report by the World Health Organization (WHO)
addressed the general importance of improving adher-
ence to long-term medical treatments [12]. The WHO
report concluded that adherence is the result of a com-
plex interaction of the social environment, patient, and
healthcare professionals. It has also been reported that
low adherence can increase the cost of treating hyper-
tension by 15-20%, and is associated with more frequent
hospitalization, use of emergency services, and admis-
sion to intensive care [13].
It has been shown that low adherence to long-term
treatment often occurs when the treatment is complex
or when the disease is asymptomatic (such as hyperten-
sion). Low adherence to AHT leads to reduced drug
effectiveness and increased risk for the development of
cardiovascular morbidities [10]. Moreover, adherence to
AHT has been reported to reduce the risk of hospitali-
zation by about 50%, and is also associated with reduced
mortality [14,15].
Previous studies have reported that the poor adher-
ence to AHT is due to patient perception that the dis-
ease is not significant, adverse drug effects, lack of
treatment effectiveness, and the patient’s poor or incom-
plete knowledge of the disease [16,17]. Clinical trials
have shown that several strategies aimed at improving
adherence to AHT were effective. A systematic review
[18] indicated that the most effective interventions were
simplification of dose regimens, reminder packaging,
social and family support, BP self-registration, follow-up
phone calls by nurses, teaching self-determination to
patients, and graphical reminders for taking medication.
Additionally, the use of multiple interventions is more
effective than use of a single intervention.
The motivational interview, defined as a clinical
patient-centered interview that helps to investigate and
resolve ambivalence in unhealthy behaviors and/or
habits to promote changes toward healthier lifestyles, is
a recent method that can be used to promote behavioral
changes in patients [19]. This process is more likely to
be successful if the patient has a positive attitude about
the need for change. Motivational interviewing is
intended to help patients recognize and address their
problems and to enhance their perception of treatment
efficacy [20]. Optimal adherence to AHT depends lar-
gely on the relationship established between the health-
care professional and patient [21]. If the healthcare
professional merely issues unilateral declarations about a
treatment plan, the patient is less likely to adopt
changes that have a positive impact on his/her health
[22]. The motivation for change is greater if a patient
and his/her healthcare professional work together to
make treatment decisions. Additionally, patient outcome
is better if the patient assumes responsibility for his/her
own circumstances (locus of control) [23]. Clinical inter-
viewing has been shown to be effective in the treatment
of alcohol problems, drug addiction, smoking, obesity,
and insufficient physical exercise.
The purpose of the present study is to evaluate the
effectiveness of a multifactorial intervention that is
designed to improve the systolic and diastolic BP of
patients who have low adherence to AHT and elevated
BP.
Methods and Design
Overview
Patients in a primary-care setting who have had low
adherence to AHT, as assessed by the Morisky-Green
or Haynes-Sackett tests, and elevated BP will be inform
and ask to sign informed consent, those patients that
agree to participate will be randomized equally to a
“multifactorial intervention” group or a control group
(which continued the usual care) (Figure 1). Partici-
pants in the intervention arm will receive three inter-
vention sessions during a 9-month period. The
intervention will be provided by study nurses who will
have received special training for administration of
motivational interviewing and in the implementation of
the study protocol.
Table 1 summarizes the measures and variables
according to the timeline. Participants will be studied
for 1 year following randomization. Primary and second-
ary outcomes will be assessed by an external nurse who
will be blinded to treatment assignment after 12
months. The primary outcome will be systolic BP. Sec-
ondary outcomes will include diastolic BP, direct costs,
and the number of patients who required treatment to
yield one patient with normalized BP.
Information bias will be minimized by use of a design
that provides the maximum possible level of masking
for studies of non-pharmacological intervention. In par-
ticular, the outcome assessor, data analyst, and physician
will all be blinded to patient allocation. Misclassification,
if any, is expected to be non-differential. Quality control
will include recording of patient adherence to interven-
tions, inclusion and follow-up monitoring, and quality
supervision of data entry. We will perform an intention-
to-treat analysis of the data; that is, the analysis will be
by randomized assignment regardless of participation in
intervention sessions.
Study population
This study will enroll 320 patients, 18-75 years of age,
who are being treated with AHT(s), remain hyperten-
sive, and have low adherence to AHT as assessed by the
Morisky-Green or Haynes-Sackett tests.
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The inclusion criteria are: age 18-75 years; poor BP con-
trol based on European Societies of Hypertension and
Cardiology (ESH/ESC) guidelines (< 140/90 mmHg or
<1 3 0 / 8 0m m H gi np a t i e n t sw ith diabetes or renal fail-
ure); and low adherence to medication as assessed by
the Morisky-Green or Haynes-Sackett tests. The exclu-
sion criteria are: presence of non-essential hypertension;
treatment by hemodialysis; and institutionalization or
terminal illness.
Randomization to treatment groups
The randomization sequence will be computer-gener-
ated, stratified by nurse and blocked in groups of two.
Study nurses will call the research units to give patient
identification numbers and will be told the randomly
assigned patient allocations. After this, participants in
the intervention group will be scheduled for their first
intervention visits.
The outcome assessors, data analyst, and physician
will be blinded to patient allocation. To evaluate the
effectiveness of blinding, these individuals will be asked
to choose the arm to which they believed each patient
was assigned (possible answers: intervention, usual care,
or unknown). If they answered “intervention” or “usual
care”, they were asked to indicate what led to that
belief.
Multifactorial Intervention
The intervention consists of five components that will
be delivered during three interventional visits of about
30 min each. Use of a detailed intervention protocol and
comprehensive motivational interview training is
intended to increase the effectiveness of interventions.
The study nurses will carefully document each compo-
nent of the multifactorial intervention that they perform
by use of specially designed intervention visitation docu-
ments and will register the time and the duration of
each component of the intervention.
The five components of the intervention are:
1. Motivational interview: This will be based on the
Health Belief Model [24] and the Prochaska and
D i C l e m e n t es t a g eo fc h a n g e[ 2 5 ] ,a n dw i l lt r yt o
resolve ambivalences that patients have regarding
medication and explore perceptions that patients
have about their ability to control events (locus of
control).
UNCONTROLLED
&L O W
ADHERENCE
PATIENTS
(n=320)
Randomization 
Usual Care Group
(160)
Intervention Group
(160)
Outcome assessment at 12 months from randomization
Intervention Nurse 
hypertensive 
consultation at 1,3, 
9 months
Figure 1 Study design Flow-chart.
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Page 3 of 82. Pillbox Reminder: A pillbox organizer with seven
compartments will be given to the patients. They
will self-fill it with one pill for each day of the week.
Use of the pillbox will be explained to patients in
the intervention group.
3. Family Support: Patients will designate one per-
son in their household who will be responsible for
reminding and monitoring medication intake. The
designated person must accept responsibility of
reminding the patient to take medication and of
supervising pill intake. If a patient lives alone or
does not wish to involve a family member or carer,
they do not need to designate anybody. Thus, this
part of the intervention is not mandatory.
4. BP measurements and AHT reminder forms:
Twelve forms (one per month) and a table will be
completed by the patient and nurse and used to
record the date and hour of all BP readings (includ-
ing gaps). AHT dosage and a telephone contact
number will also be recorded on each form. This
information will be frequently updated. The forms
will be provided to patients and nurses at visit 0,
and patients will be asked to bring them to all sub-
sequent visits.
5. Simplification of dosing regimens: AHT dosage
will be recorded at visit 0, and pharmacists will sim-
plify the dosing regimen when possible at subse-
quent visits.
Visit 1 (first month, 40 min total): motivational inter-
viewing (25 min), pill reminder (5 min), self-recording
of BP (5 min), family support, when possible (5 min).
Visit 2 (third month, 35 min total): motivational inter-
view (25 min), simplification of dosing regimen, if possi-
ble, check of self-recording BP (5 min), family support,
when possible (5 min).
Visit 3 (ninth month, 35 min total): motivational inter-
view (25 min), check self-recording BP (5 min), and
family support, when possible (5 min).
Control group
Patients randomized to the control group will not
receive any changes in their care. However, they will be
contacted at baseline and at the 12th month and asked
to complete the same outcome measures as the inter-
vention group.
Training
The intervention nurses will attend a 16-h motivational
interview training program to teach the theoretical
underpinnings, principles, and “spirit” of motivational
intervention and practical exercises (to be supervised by
co-investigators Rosa Duro and Alfonso Leiva). This
training program will include a thorough discussion of
the study protocol and will instruct nurses to use terms
consistently when recording the findings and document-
ing treatments on the intervention visitation documents.
There will also be hands-on training sessions to ensure
that the intervention nurses are comfortable with the
protocol and the types of questions that participants
may ask. The intervention nurses will also practice com-
pleting intervention forms and providing suggestions for
self-care.
Assessment of outcomes
Primary outcome measure
The primary outcome measure is systolic BP at 12
months. BP will be measured according to ESH/ESC
guidelines. Patients (instructed to not eat or smoke for
30 min) will be seated quietly, with their backs sup-
ported and feet on the floor for 5 minutes. Then, using
an appropriately sized cuff, the bared arm will be sup-
ported, and an oscillometric BP machine with a printer
will be used for three measurements. The nurse (blinded
to patient allocation) will write all three BP measure-
ments on the final visit form.
Secondary outcome measures
Secondary outcomes are diastolic BP, proportion of par-
ticipants with adequate BP control at 12 months, total
direct cost, absolute and relative risk reduction, number
of patients need to treat for benefit, and change in
adherence at 12 months (measured by the Haynes-Sack-
ett test).
Table 1 Measures, variables and timeline
VISIT -1 0123 4
Time (months) -1 01391 2
Blood pressure measurement
inclusion criteria
XX
Morisky-Green and Haynes-Sackett tests X
Inclusion and exclusion criteria X
Comorbidities X
Blinded blood pressure measurement X
Medication use X
Adverse effects to medication X X
Medical consultation, cardiovascular
events and hospital admission.
X
Checklist and time duration of
intervention components
(Intervention group)
XXX
Motivational interview
(Intervention group)
XXX
Pill reminder
(Intervention group)
X
Family support
(Intervention group)
XXX
Blood pressure self-recording
(Intervention group)
XXX
Simplification of dosing regimens
(Intervention group)
X
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Sample size, clinical significance, statistical significance
We want to ensure that our clinical trial has adequate
statistical power to detect a clinically significant differ-
ence of at least 6 mmHg at 1 year in systolic BP
between groups with a two-tailed significance level of
0.05. Assuming a standard deviation of 15 mmHg and a
20% loss to follow-up, we would need to randomize 110
participants per group. We expect a 15% “contamina-
tion” of the control group (see below), yielding a 1.41
contamination effect [26]. Thus, the final target sample
size is 320 patients.
The effectiveness of the intervention will be assessed
by a clinically significant reduction in BP, cardiovascular
mortality models shows an estimated 5-yr risk reduction
of cardiovascular disease of 15-20% by a reduction of 5
mmHg in systolic blood pressure [27,28]. We have esti-
mated that a difference of at least 10 mmHg at 1-yr is
necessary to detect a clinically significant difference of
at least 5 mm Hg at 5-yr.
Intervention will be provided to a group of partici-
pants by a single nurse, so we will consider the cluster
effect during statistical analysis.
Data collection and management
We will collect informationo no u t c o m ea te v e r ys t a g e
of the recruitment, randomization, treatment allocation,
follow-up, and analysis so that we can report patient
flow according to CONSORT guidelines [29]. We will
record the number of patients who qualified for inclu-
sion but who were not willing to participate, the number
of patients assigned to the intervention arm, the number
of patients assigned to the control arm, the number of
intervention visits, the number of patients who provide
follow-up data, the number of patients who complete
the trial and are included in the analysis, and the num-
ber of withdrawals.
We will implement procedures to ensure that rando-
mization proceeds as planned, that clinical data collec-
tion forms are accurately entered into databases, and
that data are accurately transferred and retrieved as
needed. We will use a relational database to track infor-
mation during recruitment, randomization, treatment,
and assessment so that we can report patient flow auto-
matically and in an integrated fashion by use of standard
automated reports. To ensure accurate transfer of infor-
mation, all data system processes will be thoroughly
tested prior to recruitment. Procedures to protect the
confidentiality and integrity of the databases and docu-
m e n t sw i l lb er e v i e w e db yt h ebiostatistician prior to
patient recruitment and periodically during the study.
To maintain the confidentiality of patient information,
all patients will be identified by study numbers. The
password security system will be used to assign appro-
priate levels of computer privileges to different database
users to ensure that all personnel remain blinded. Com-
puter files with patient names will be password-pro-
tected, with access restricted to staff who use this
information to recruit patients, obtain follow-up data,
and interact with patients who report adverse events.
During the intervention phase of the trial, we will con-
tinuously monitor the nurses’ interventions and provide
focused supplemental training as needed. After auditing
to ensure adherence to the protocol, initials from the
charts will be removed and stored in locked filing cabi-
nets that are only accessible to study personnel. All data
analysis files will be password protected.
Protection of human subjects and assessment of safety
Our study protocol was approved by the Primary Care
Research Committee and Mallorca Ethical Committee of
Clinical Research (IB 969/08 PI).
Adverse Events
Participants will be asked about adverse events at each
visit. We define an adverse event as any unfavorable or
unintended sign, symptom, or disease that could reason-
ably be associated with the use of AHT. If a patient
develops a serious adverse event (death, a life-threaten-
ing event, inpatient hospitalization or prolongation of
existing hospitalization, persistent or significant disabil-
ity/incapacity, cancer, or fetal exposure) during the
course of the study, it will be reported to the Spanish
Agency of Medication Registry for Drug Adverse Events.
Statistical Analysis
The primary statistical analysis will determine if our
multifactorial intervention to improve AHT adherence
is effective in lowering systolic BP and if the interven-
tion is cost-effective. We will use intention-to-treat ana-
lysis for all data analyses; that is, all randomized patients
will be included in the analysis, regardless of participa-
tion in any treatment sessions. This approach reduces
the bias that may occur when participants who do not
receive assigned treatments are excluded from analysis.
All tests will be two-sided and a- v a l u e so f0 . 0 5w i l lb e
considered statistically significant.
We will test for significant differences between base-
line characteristics of control and intervention groups.
We will perform descriptive analysis, with continuous
variables summarized by their means and standard
deviations for normal distributions, and by median and
25
th and 75th percentiles for non-normal distributions.
In bivariate analysis, we will compare systolic and dia-
stolic BP between the intervention and control groups
at visit 4 (12th month) using the Student’s t-test if both
sample groups had normal distributions or the Mann-
Whitney U test against the usual null hypothesis of no
difference between means if the sample groups had
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Page 5 of 8non-normal distributions. We will also calculate 95%
confidence intervals to assess the clinical significance of
our treatment.
In multivariate analysis, we will adjust for clinical iner-
tia (physicians blinding and number of medication
changes) in a multiple linear regression model.
We will test for a significant difference in the percentage
of patients with controlled BP (according to ESH/ESC
guidelines) in the intervention and control groups using
the c
2 test. We will estimate relative and absolute risk
reduction and the number needed to treat, defined as the
estimated number of patients who need to be treated with
the intervention (rather than the usual care) for one addi-
tional patient to be controlled. The 95% confidence inter-
vals for these calculations will be provided. The number
needed to treat is calculated as the reciprocal of the differ-
ence between the proportion of patients controlled in the
intervention group and the control group.
An analysis of direct costs and outcomes for patients
in both groups will be conducted by a nurse blinded to
patient allocation. Clinical record review and detailed
self-reported data on costs of healthcare utilization, clin-
ical tests, and medication will be considered. All
resources utilized will be multiplied by the appropriate
cost using nationally applicable cost data. The cost of
resource utilization (primary care visits, hospital admis-
sions, clinical testing) will be estimated using the health-
care costs published in the National Official Journal of
Spain or Regional Officials Journal. Costs of all AHTs
will be calculated using prices published in the catalogue
of pharmaceutical compounds by the Spanish Board of
Pharmacists. Intervention costs will also consider the
time needed to train nurses and the time of each inter-
vention visit.
The primary health outcome for the cost analyses is
BP reduction, which will be calculated using direct
costs. The measure of “relative value for money” from
the intervention is the incremental cost-effectiveness
ratio calculated from the additional cost for a benefit of
1 mmHg reduction.
Analysis of costs may require variable transformation,
but can be modeled using multivariate linear regression
without a baseline value for costs because this value will
be unknown. We will adjust for age, sex, and comorbid-
ities that may affect cost. We recognize that we will
have low statistical power to detect even moderate cost
differences between the two groups.
Each nurse will provide intervention to a group of
patients, so we will also measure the effect of individual
nurses on outcome by multilevel analysis to determine if
there is a significant variation across nurses that cannot
be explained by random variation, also we will establish
a number maximum of 10 patients per nurse to mini-
mize this effect.
Limitations
Control patients are allowed to visit study nurses during
the study period so “contamination” of the control
g r o u pi sp o s s i b l e .T h i sw o u l dr e d u c et h ep o i n te s t i m a t e
of the intervention’s effectiveness and may lead to a
type II error. In other words, an effective intervention
could be classified as ineffective because the observed
effect size was neither statistically nor clinically signifi-
cant. We will try to overcome this problem by using a
l a r g es a m p l es i z e( n=3 2 0 )based on the assumption
that there will be a 15% contamination rate.
Clinical inertia is an important factor associated with
poor BP control [7]. As relevant to our study, physicians
of the intervention patients may be more prone to
change medications if they know that their patients are
involved in a clinical trial of BP control. The possibility
of this effect will be significantly reduced by blinding
physicians to patient allocation. However because
patients are not blinding to treatment, physicians could
easily find out patient allocation. We will retrospectively
review the medication records to determine if there
were differences in the number of medication changes
in the two treatment arms and we will evaluate the
effectiveness of the blinding by direct interview. We will
control in a multivariate analysis by number of medica-
tion changes and physicians blinding (yes/no).
There will be a tendency of BP values, when selecting
patient non optimally controlled, to resemble their
mean. Randomized trials with a control group avoid
regression toward the mean because BP values fell in
both treated and placebo groups, but it fell by more in
the treated group.
In most non-pharmacological randomized controlled
trials where follow-up visits are part of the intervention,
follow-up visits in the control group are common. Thus,
an undesirable “Hawthorne effect” could mask the
effects of our intervention. To avoid this problem, the
effects of the intervention will be compared with a con-
trol group without protocol-stipulated follow-up visits.
The ideal outcome measures for our trial are reduc-
tion of cardiovascular events and/or total mortality.
However, such a study would be very expensive because
i tw o u l dr e q u i r eav e r yl a r g es a m p l es i z ea n dv e r yl o n g
study period. The use of clinically relevant reduction of
BP (a surrogate marker) allows us to perform this study
with a more manageable number of patients (n = 320)
in a relatively short period of time (12 months).
Discussion
Unfortunately, patient adherence to AHT is sub-optimal,
and BP levels remain above recommended guidelines for
many AHT patients. Increasing the support provided to
patients and investigating patients’ beliefs about treat-
ment are likely to improve adherence. Our study will
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tion program applied in a primary care setting leads to
improved control of BP. Adherence interventions could
improve the effectiveness and efficacy of pharmacother-
apy and could help reduce future healthcare costs asso-
ciated with the long-term consequences of uncontrolled
hypertension.
Recent studies of AHT [14,15] have reported that
there was a significantly decreased risk of cardiovascular
events in the high adherence groups (>80%) compared
with low adherence groups (<40%).
Efforts to develop novel antihypertensive agents are
expensive and likely to yield drugs whose efficacy does
not differ significantly from existing blood pressure low-
ering agents in terms of major cardiovascular events,
cardiovascular death, and total mortality [4]. By contrast,
development of an effective adherence-based interven-
tion could provide better results at a lower cost.
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